Country: Georgia

Currently showing 1 clinical trials. Use pagination links to see more trials.

Select your city to get better results

Select your region to filter trials in your city or near you.

  • CT-EU-00115472

    To evaluate the safety and effects of GS-0272 in patients with rheumatoid arthritis or lupus

    A clinical trial is being introduced focusing on a new drug called GS-0272, intended for people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The goal of this study is to gather more information about GS-0272, especially regarding its safety and good tolerability when administered in multiple doses.

    The Phase 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of GS-0272 in adult participants with rheumatoid arthritis or systemic lupus erythematosus. The study will be conducted at multiple sites, and participants will be randomly assigned to receive the study drug GS-0272 or a placebo administered subcutaneously.

    The main goals of this study are to understand how safe GS-0272 is and how participants’ bodies respond to it after receiving multiple doses. Adverse events or serious adverse events will be closely monitored, as will any changes in laboratory test results that may indicate that the medicine is not well tolerated. Additionally, the study will examine how GS-0272 travels and is processed by the body, which is known as pharmacokinetics.

    This study is an important step in determining whether GS-0272 may be a beneficial treatment option for people with RA or SLE. The safety and well-being of participants are the highest priority and a commitment has been made to provide all necessary information and support throughout the study.

    • GS-0272- new potential medication for Rheumatoid Arthritis and Systemic Lupus Erythematosus
    • placebo